Takeda Drug Pipeline

Takeda maintains a substantial clinical portfolio, with 78 active trials and a total of 826 trials registered since 2008. These active programs span from Phase 1 through Phase 4, with the largest concentration in Phase 3 (44 trials), followed by Phase 2 (26 trials). Takeda’s research activity covers 18 therapeutic areas, but is heavily weighted toward Immunology, which accounts for 37% of active programs (29 trials). Within Immunology, Crohn's Disease (13 active trials, 7 in Phase 3) and Ulcerative Colitis (9 active trials, 5 in Phase 3) are the most active indications. Oncology (20 active trials) represents the next largest area of focus, followed by Rare Disease and Sleep (3 active trials each), CNS (2 active trials), and Cardiovascular (1 active trial). The portfolio's significant Phase 3 presence suggests a focus on late-stage development and potential near-term market catalysts.